68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)

Summary

This was an open-label, multicenter, single dose, Phase I/II study to evaluate the safety and tolerability of a single administration of 3 mega Becquerel (MBq)/kg, but not less than 150 MBq and not more than 250 MBq, of 68\^Ga-PSMA-R2 in adult male patients with biochemical relapse (BR) and metastatic prostate cancer (mPCa).

Timeline

Start

2018-05-23

Primary completion

2019-08-20

Completion

2019-09-13

Publications

• Lindenberg L, Hope TA, Lin FI, Rowe SP, Pucar D, Gilbert N, Chicco D, He B, Feuerecker B, Castaldi E, Solnes LB. Safety, Dosimetry, and Feasibility of [68Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer. J Nucl Med. 2025 Mar 3;66(3):359-365. doi: 10.2967/jnumed.124.268318.

Drugs

Indications